| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.095 | 0.01 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | 0.092 | 0.01 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | -0.094 | 0.01 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | 0.13 | 0.01 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | -0.092 | 0.01 |
| mRNA | PF-3758309 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.01 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.088 | 0.01 |
| mRNA | AZD6482 | CTRPv2 | pan-cancer | AAC | -0.094 | 0.01 |
| mRNA | BRD-M00053801 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.01 |
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | 0.095 | 0.01 |